Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
NOX5 as a therapeutic target in cerebral ischemic injury
Luciana Simão do Carmo, … , Bradford C. Berk, David G. Harrison
Luciana Simão do Carmo, … , Bradford C. Berk, David G. Harrison
Published March 18, 2019
Citation Information: J Clin Invest. 2019;129(4):1530-1532. https://doi.org/10.1172/JCI127682.
View: Text | PDF
Commentary

NOX5 as a therapeutic target in cerebral ischemic injury

  • Text
  • PDF
Abstract

In this issue of the JCI, Casas et al. define a previously unknown role of the NADPH oxidase catalytic subunit NOX5 in cerebral infarction. Using a mouse expressing human NOX5 in the endothelium, the investigators show that NOX5 is activated and plays a deleterious role in promoting edema, infarction, and ultimately, worsened neurological function following cerebral ischemia. They provide evidence that this is due to the breakdown of the blood-brain barrier (BBB) and that a unique pharmacological inhibitor of NOX5, ML090, if given early, around the time of reoxygenation, can maintain BBB integrity. Future studies of NOX5 inhibition in humans, particularly in the setting of thrombolysis, are warranted.

Authors

Luciana Simão do Carmo, Bradford C. Berk, David G. Harrison

×

Figure 1

The role of NOX5 in BBB breakdown.

Options: View larger image (or click on image) Download as PowerPoint
The role of NOX5 in BBB breakdown.
(A) Schematic of the NOX5 protein con...
(A) Schematic of the NOX5 protein containing calcium-binding (EF-hand) and NADPH- and FAD-binding sites. (B) Under normal conditions, the BBB has tight paracellular junctions and low permeability. Upon ischemia/reperfusion, intracellular calcium increases, leading to the activation of NOX5 and production of ROS including superoxide (O2–), peroxynitrite (OONO–), and hydrogen peroxide (H2O2). These promote loss of BBB integrity, leading to the entry of injurious macromolecules, inflammatory cells, and other toxins that cause progressive brain injury. Illustration by Rachel Davidowitz.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts